RESOURCES

Clinical attrition of drug candidates is frequently driven by unforeseen safety liabilities, which are often associated with off-target pharmacological interactions.

Secondary pharmacology is increasingly used to identify off-target activities with potential clinical safety relevance.

Suzetrigine, the first FDA-approved non-opioid analgesic targeting hNav1.8, marks a pivotal moment in the evolution of pain therapeutics.

Secondary pharmacology identifies off-target interactions that may drive undesirable clinical effects, supporting lead optimization, candidate selection for early risk assessment

In early drug discovery, Caco-2 cells are widely used to estimate intestinal permeability.

Neurotoxicity is a major cause of drug attrition with central nervous system (CNS) affected the most.

WEE1 is a key regulator of the G2/M cell cycle checkpoint, inhibiting CDK1 to allow DNA repair before mitosis.

Clinical attrition of drug candidates is frequently driven by unforeseen safety liabilities, which are often associated with off-target pharmacological interactions.

The Adenosine A_2A Receptor (A_2AR) was selected as a representative GPCR to establish an integrated fragment‑based discovery workflow capable of screening fragments on the active receptor state.

We present integrated capabilities for SH2 domain-focused drug discovery, emphasizing STAT protein binding affinity and targeted protein degradation (TPD).

Obesity is a chronic, multifactorial disease projected to affect over 50% of the global population by 2035.

WEE1 is a key regulator of the G2/M cell cycle checkpoint, inhibiting CDK1 to allow DNA repair before mitosis.